Viral RNA Degradation Makes Urine a Challenging Specimen for Detection of Japanese Encephalitis Virus in Patients With Suspected CNS Infection.
Japanese encephalitis virus
RNA
RT-qPCR
diagnosis
flavivirus
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
11
2018
revised:
23
01
2019
accepted:
31
01
2019
entrez:
19
3
2019
pubmed:
19
3
2019
medline:
19
3
2019
Statut:
epublish
Résumé
Japanese encephalitis virus (JEV) is a leading cause of central nervous system (CNS) infections in Asia and results in significant morbidity and mortality. JEV RNA is rarely detected in serum or cerebrospinal fluid (CSF), and diagnosis of JEV infection is usually based on serological tests that are frequently difficult to interpret. Unlike serum or CSF, urine is relatively easy to obtain, but, to date, there has been minimal work on the feasibility of testing urine for JEV RNA. We investigated the use of lysis buffer and a Microsep device to optimize urine storage for detection of JEV RNA by reverse transcription real-time polymerase chain reaction (RT-qPCR). The best of the studied methods was then evaluated in consecutive patients admitted to the hospital with suspected CNS infections in Laos. We demonstrated degradation of JEV RNA in urine after even short storage periods at 4°C or -80°C. Although there was no advantage in using a Microsep concentration device alone, immediate addition of lysis buffer to fresh urine improved the detection of JEV RNA at the limit of detection. In 2 studies of 41 patients with acute encephalitis syndrome, 11 (27%) were positive for JEV IgM in CSF and/or serum, and 2 (4.9%) were JEV RT-qPCR positive from throat swabs. JEV RNA was not detected in any of these patients' urine samples. However, lysis buffer was only used during a prospective study, that is, for only 17/41 (41%) patient urine samples. Our findings suggest a need for larger studies testing urine for JEV RNA, with urine collected at different times from symptom onset, and using lysis buffer, which stabilizes RNA, for storage.
Sections du résumé
BACKGROUND
BACKGROUND
Japanese encephalitis virus (JEV) is a leading cause of central nervous system (CNS) infections in Asia and results in significant morbidity and mortality. JEV RNA is rarely detected in serum or cerebrospinal fluid (CSF), and diagnosis of JEV infection is usually based on serological tests that are frequently difficult to interpret. Unlike serum or CSF, urine is relatively easy to obtain, but, to date, there has been minimal work on the feasibility of testing urine for JEV RNA.
METHODS
METHODS
We investigated the use of lysis buffer and a Microsep device to optimize urine storage for detection of JEV RNA by reverse transcription real-time polymerase chain reaction (RT-qPCR). The best of the studied methods was then evaluated in consecutive patients admitted to the hospital with suspected CNS infections in Laos.
RESULTS
RESULTS
We demonstrated degradation of JEV RNA in urine after even short storage periods at 4°C or -80°C. Although there was no advantage in using a Microsep concentration device alone, immediate addition of lysis buffer to fresh urine improved the detection of JEV RNA at the limit of detection.
CONCLUSIONS
CONCLUSIONS
In 2 studies of 41 patients with acute encephalitis syndrome, 11 (27%) were positive for JEV IgM in CSF and/or serum, and 2 (4.9%) were JEV RT-qPCR positive from throat swabs. JEV RNA was not detected in any of these patients' urine samples. However, lysis buffer was only used during a prospective study, that is, for only 17/41 (41%) patient urine samples. Our findings suggest a need for larger studies testing urine for JEV RNA, with urine collected at different times from symptom onset, and using lysis buffer, which stabilizes RNA, for storage.
Identifiants
pubmed: 30882014
doi: 10.1093/ofid/ofz048
pii: ofz048
pmc: PMC6411208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz048Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
J Virol Methods. 2005 Feb;123(2):163-9
pubmed: 15620398
Int J Infect Dis. 2010 Sep;14 Suppl 3:e79-84
pubmed: 20346721
Am J Trop Med Hyg. 2010 Nov;83(5):1146-55
pubmed: 21036854
PLoS One. 2011 Feb 09;6(2):e16142
pubmed: 21347398
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
Genome Announc. 2013 Jan;1(1):
pubmed: 23469339
Clin Infect Dis. 2013 Jul;57(1):157-8
pubmed: 23487381
J Infect Dis. 2013 Oct 1;208(7):1086-92
pubmed: 23821721
Emerg Infect Dis. 2015 Jan;21(1):84-6
pubmed: 25530324
Rev Med Virol. 2015 Jul;25(4):203-4
pubmed: 25943825
PLoS Negl Trop Dis. 2015 Sep 25;9(9):e0004100
pubmed: 26406240
Lancet Infect Dis. 2015 Dec;15(12):1376-7
pubmed: 26607119
Am J Trop Med Hyg. 2016 Apr;94(4):820-828
pubmed: 26856911
Nat Commun. 2016 Feb 23;7:10832
pubmed: 26902924
Arch Virol. 2016 Jul;161(7):1797-806
pubmed: 27038827
N Engl J Med. 2017 Apr 13;376(15):1483-1485
pubmed: 28402771
J Virol Methods. 2017 Oct;248:66-70
pubmed: 28472623
Open Forum Infect Dis. 2017 Mar 04;4(2):ofx046
pubmed: 28480297
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):579-583
pubmed: 28594790
Open Forum Infect Dis. 2017 Sep 27;4(4):ofx203
pubmed: 29226169
PLoS One. 2018 Mar 23;13(3):e0194412
pubmed: 29570739
Nat Rev Neurol. 2018 Apr 26;14(5):298-313
pubmed: 29697099
Sci Rep. 2018 May 22;8(1):8018
pubmed: 29789537
Curr Infect Dis Rep. 2018 Jun 29;20(9):30
pubmed: 29959548
J Med Virol. 2019 Jan;91(1):115-123
pubmed: 30091789
Am J Trop Med Hyg. 2019 Feb;100(2):427-433
pubmed: 30560770